[go: up one dir, main page]

AR003928A1 - Comprimido del liberacion controlada - Google Patents

Comprimido del liberacion controlada

Info

Publication number
AR003928A1
AR003928A1 ARP960101520A AR10152096A AR003928A1 AR 003928 A1 AR003928 A1 AR 003928A1 AR P960101520 A ARP960101520 A AR P960101520A AR 10152096 A AR10152096 A AR 10152096A AR 003928 A1 AR003928 A1 AR 003928A1
Authority
AR
Argentina
Prior art keywords
polymer
tablet
pharmaceutical agent
rate
water
Prior art date
Application number
ARP960101520A
Other languages
English (en)
Original Assignee
Univ Temple
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Temple filed Critical Univ Temple
Publication of AR003928A1 publication Critical patent/AR003928A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)

Abstract

Un comprimido de liberación controlada que incluye un agente farmacéutico y un excipiente. El excipiente incluye por lo menos 50% de polímero susceptiblede hincharse con agua y un lubricante. El polímero susceptible de hincharse con agua seselecci ona de manera que la velocidad de hinchado del polímero seaigual a la velocidad de disolución de polímero hinchado. Además, el excipiente puede incluir otros ingredientes tales como diluyentes, soportes, ligantes yotros compuestosfarmacológicamente inactivos. El polímero se selecciona teniendo en cuenta el agente farmacéutico, de manera que el comprimido sedisuelva completamente al mismo tiempo que se libera la última porción del agente farmacéutico.
ARP960101520A 1995-02-28 1996-02-26 Comprimido del liberacion controlada AR003928A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39579295A 1995-02-28 1995-02-28

Publications (1)

Publication Number Publication Date
AR003928A1 true AR003928A1 (es) 1998-09-30

Family

ID=23564527

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960101520A AR003928A1 (es) 1995-02-28 1996-02-26 Comprimido del liberacion controlada

Country Status (11)

Country Link
EP (1) EP0821582B1 (es)
JP (1) JPH11509169A (es)
AR (1) AR003928A1 (es)
AT (1) ATE228829T1 (es)
AU (1) AU722741B2 (es)
CA (1) CA2213455A1 (es)
DE (1) DE69625189D1 (es)
MY (1) MY113429A (es)
PA (1) PA8388101A1 (es)
TW (1) TW431891B (es)
WO (1) WO1996026718A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945125A (en) * 1995-02-28 1999-08-31 Temple University Controlled release tablet
WO1998029095A2 (en) * 1997-01-03 1998-07-09 Elan Corporation, Plc Sustained release cisapride mini-tablet formulation
US6090411A (en) * 1998-03-09 2000-07-18 Temple University Monolithic tablet for controlled drug release
ES2270982T3 (es) 2000-02-04 2007-04-16 Depomed, Inc. Forma de dosificacion de nucleo y carcasa que se aproxima a una liberacion del farmaco de orden cero.
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6723340B2 (en) * 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
AU2004204825B2 (en) 2003-01-13 2007-07-19 Dynogen Pharmaceuticals, Inc. Method of treating functional bowel disorders
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
WO2006009769A1 (en) 2004-06-17 2006-01-26 Forest Laboratories, Inc. Modified release formulation of memantine
EP1954257A4 (en) 2005-10-14 2009-05-20 Lundbeck & Co As H METHOD FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM WITH A LOW-DOSED COMBINATION OF ESCITALOPRAM AND BUPROPION
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US20070202164A1 (en) * 2006-02-28 2007-08-30 Hutchison Medipharma Enterprises Limited Andrographis Extract Formulations
WO2010026467A2 (en) 2008-09-04 2010-03-11 Torrent Pharmaceuticals Ltd. Controlled release dosage form of high solubility active ingredient
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
CN102481276A (zh) 2009-04-20 2012-05-30 埃尔舍利克斯治疗公司 基于化学感受受体配体的治疗法
US8828953B2 (en) 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
WO2012054523A2 (en) 2010-10-19 2012-04-26 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
CA2823397C (en) 2011-01-07 2020-03-10 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
EP3878445A3 (en) 2013-06-05 2021-10-27 Synchroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US9617230B2 (en) 2014-12-22 2017-04-11 Farmington Pharma Development Creatine prodrugs, compositions and methods of use thereof
US11332438B2 (en) 2017-12-01 2022-05-17 Ultragenyx Pharmaceutical Inc. Creatine prodrugs, compositions and methods of use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252338A (en) * 1991-06-27 1993-10-12 Alza Corporation Therapy delayed

Also Published As

Publication number Publication date
JPH11509169A (ja) 1999-08-17
AU5171196A (en) 1996-09-18
EP0821582A2 (en) 1998-02-04
PA8388101A1 (es) 1997-09-30
AU722741B2 (en) 2000-08-10
MY113429A (en) 2002-02-28
CA2213455A1 (en) 1996-09-06
WO1996026718A3 (en) 1996-10-10
EP0821582B1 (en) 2002-12-04
WO1996026718A2 (en) 1996-09-06
DE69625189D1 (de) 2003-01-16
TW431891B (en) 2001-05-01
ATE228829T1 (de) 2002-12-15

Similar Documents

Publication Publication Date Title
AR003928A1 (es) Comprimido del liberacion controlada
AR003908A1 (es) Tableta de liberacion controlada
AR054782A2 (es) Composiciones farmaceuticas y tabletas que contienen irbesartan en combinacion con un diuretico
CL2004001182A1 (es) Composicion farmaceutica que comprende a una microparticula de liberacion sostenida la que contiene a un derivado de 1,2 benzazol; procedimiento de preparacion de la microparticula; util como broncodilatador, antipsicoticos y en otros problemas del s
KR880009639A (ko) 서방성 매트릭스 제형
BG105568A (en) Pharmaceutical compositions for modified release of an insulin sensitiser and another antidiabetic agent
ES2177592T3 (es) Nanoparticulas biocompatibles y biodegradables para la absorcion y administracion de medicamentos proteinicos.
AR002754A1 (es) Composición farmacéutica que comprende bacterias lactobacillus viables micro-encapsuladas, y uso de la composición para preparar de un medicamento
GT199900151A (es) Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial.
AR001405A1 (es) Formulación oral de 2-metil-tieno-beno-diacepina.
ES2172242T3 (es) Composiciones oftalmicas de liberacion mantenida conteniendo medicamentos solubles en agua.
BR9708772A (pt) "comprimidos famacêuticos de liberação controlada que contém um veìculo à base de amilose reticulada e hidróxi propil metil celulose"
BR9509019B1 (pt) comprimido isento de solventes orgÂnicos.
ES2172782T3 (es) Medicamento a base de progesterona y de estradiol.
ES2111547T3 (es) Comprimido de liberacion prolongada.
ES2088956T3 (es) Estructura de tableta multifraccionable.
EA200001201A3 (ru) Таблетка с основой, позволяющая осуществлять пролонгированное высвобождение триметазидина после введения оральным путем
ATE219061T1 (de) Huperzin a analoge verbindungen
HRP20010684B1 (hr) Izravno stlaciva matrica za kontrolirano otpustanje jednostruke dnevne doze klaritromicina
BG105570A (en) Pharmaceutical compositions for modified release insulin sensitiser
CZ15295A3 (en) Solid pharmaceutical dosing unit
ATE295157T1 (de) Mittel zur transdermalen verabreichung von arzneistoffen
BR0113372A (pt) Composição farmacêutica com carreador modificado, método de fabricação da mesma e seus usos
ES2190581T3 (es) 2-aminotetralina opticamente activa, procedimiento para su preparacion y composiciones farmaceuticas que la contienen, activa en la prevencion y tratamiento de shock septico.
ES2127305T3 (es) Una forma farmaceutica para la administracion rectal de compuestos farmacologicamente activos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure